Format

Send to

Choose Destination
Curr Opin Pharmacol. 2004 Dec;4(6):589-96.

Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.

Author information

1
Department of Medical Physiology, University of Copenhagen, The Panum Institute, DK-2200 Copenhagen N, Denmark. holst@mfi.ku.dk

Abstract

Proof-of-concept for the efficacy of a glucagon-like peptide 1 (GLP-1)-based therapy of patients with type 2 diabetes was provided in 2002 by means of prolonged continuous subcutaneous infusion of native GLP-1. Since then, several long-acting analogues of GLP-1, as well as inhibitors of dipeptidyl peptidase IV, the enzyme that rapidly inactivates endogenous GLP-1, have demonstrated efficacy in long term clinical trials.

PMID:
15525549
DOI:
10.1016/j.coph.2004.08.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center